Testing a new intravenous treatment for lung scarring disease

Plain-English translation of NCT07447102 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This research study is testing a new medication called to see if it can help slow or improve idiopathic pulmonary fibrosis (IPF), a serious disease where the lungs gradually become scarred and stiff, making it harder to breathe. is given through an IV infusion (a tube into your vein) every two weeks for 24 weeks. The study will compare this medication to a placebo (a dummy treatment) to see if it actually works and is safe.

Idiopathic pulmonary fibrosis is a progressive disease with few treatment options, and the medications currently available don't work for everyone or may not be strong enough. This trial exists to see whether this new treatment might offer patients another option to help preserve or improve lung function.

Do you qualify?

You likely qualify if…

you are 40 years old or older
you have been diagnosed with idiopathic pulmonary fibrosis (confirmed by imaging or lung biopsy)
you have moderate lung function (FVC at least 45% of predicted, DLCO between 30% and 90% of predicted)
you are either on a stable dose of nintedanib or pirfenidone for at least 8 weeks, or you have not taken these drugs and do not plan to start them during the study
you are willing to use reliable birth control if you are of reproductive age

You likely don't qualify if…

you have lung disease from a known cause (such as occupational exposure, autoimmune disease, or medication toxicity)
you have severe emphysema (50% or more of your lungs) or emphysema that is worse than the scarring
you had a sudden worsening of your IPF in the past 3 months
your lung disease has improved significantly in the past 12 months
you have other significant lung diseases like asthma or COPD

What participation looks like

You would visit the study clinic every two weeks for 24 weeks to receive an IV infusion of either the new medication or a placebo. The study has two parts: first, an open-label safety phase where everyone receives the active medication, followed by a randomized phase where you have a 50/50 chance of receiving the medication or placebo. During your visits, you'll have breathing tests, imaging scans, and blood work to monitor how your lungs are responding and how you're tolerating the treatment.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

China

Dragonboat Biopharmaceutical,Co.,Ltd, Shanghai, Shanghai Municipality